MKI67 and breast cancer: The guidelines of the American Society of Clinical Oncology (ASCO) do not include Ki-67 as one of the required biological markers to routinely investigate when examining breast cancer patients [12] despite the growing body of evidence showing that it is a clinically useful and widely accepted biomarker.